Melphalan forever? Evidenz und Trends in der Therapie des Multiplen Myeloms

Schlüsselwörter

Multiples Myelom - autologe Stammzelltransplantation - hochdosierte Chemotherapie - Lenalidomid - Bortezomib - Dexamethason

Keywords

multiple myeloma - autologous stem cell transplantation - high-dose chemotherapy - lenalidomide - bortezomib - dexamethasone

• Literatur

• 1 Bashir Q, Khan H, Orlowski RZ et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2011; Dec 17. doi: DOI: 10.1002/ajh.22273. [Epub ahead of print]
• 2 Björkstrand B, Iacobelli S, Hegenbart U et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: 3016-3022
• 3 Cavo M, Rajkumar SV, Palumbo A et al. International Myeloma Working Group consensus approch to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073
• 4 Cavo M, Taccheti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085
• 5 Eleftherakis-Papapiakovou E, Kastritis E, Roussou M et al. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia Lymphoma 2011; 52: 2299-2303
• 6 Fayers PM, Palumbo A, Hulin C et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011; 118: 1239-1247
• 7 Hutchison CA, Batuman V, Behrens J et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature Review Nephrology 2012; 8: 43-51
• 8 Knop S, Liebisch P, Hebart H et al. Up fronr allogeneic stem cell transplant is superior to tandem high-doe melphalan in cytogenetically defined ultra high-risk myeloma. Onkologie 2011; 34 (Suppl. 06) Abstract V677
• 9 Krishnan A, Pasquini MC, Logan B et al. Autologous haematopoietic stem-cell transplantation followed by allogeneic or autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase I biological assessment trial. Lancet Oncol 2011; 12: 1195-1203
• 10 Mateos MV, Oriol A, Martínez-López J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11: 934-941
• 11 Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999
• 12 Neben K, Lokhorst HM, Jauch A et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2011; Dec 8. [Epub ahead of print]
• 13 Palumbo A, Cavallo F, Hardan A et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients <65 years: Results of a randomized phase III study. Blood (ASH Annual Meeting Abstracts) 2011; 118 Abstract 3069
• 14 San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917
• 15 San Miguel JF, Schlag R, Khuageva NK et al. Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 476
• 16 Zonder JA, Mohrbacher AF, Singhal S et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2011; Dec 19. [Epub ahead of print]